Clinical trials
CAR clinical trials
Below are recruiting car clinical trials, each written for real people, not researchers. We’re tracking 733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06635330RecruitingPhase 1/Phase 2
CAR T cell therapy for children with relapsed B-cell leukemia
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
Tehran, Tehran ProvinceAges 2–18 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06644443RecruitingPhase 1/Phase 2
BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Shenzhen, GuangdongAges 18–75 - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07668557RecruitingPhase 1
CLL1-CD33 CAR-T cells for relapsed or refractory acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Nanchang, JiangxiAges 18–70 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07627698RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Melanoma
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT06698484RecruitingPhase 2
CAR-T cell therapy for B-cell lymphoma that has returned or not responded
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
Bandar Tun Razak, Kuala LumpurAges 13–75 - NCT07617285RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
BeijingAges 18–70 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07587840RecruitingPhase 2
CAR-T Cell Therapy After Initial Treatment for Follicular Lymphoma
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Beijing, Beijing MunicipalityAges 18–85
Hear when a new CAR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car?
- Yes. Clin2 currently lists 733 recruiting car studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.